Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Chemotherapy plus hyperthermia therapy improves anti-cancer treatment outcomes

BSD Medical : 13 February, 2008  (New Product)
A major presentation has been delivered by Dr Rolf Issels at the 19th International Congress on Anti-Cancer Treatment (ICACT) held this month in Paris, France, addressing the use of hyperthermia therapy (through BSD Medical’s BSD-2000) to reduce the risk of early disease progression in high-grade soft-tissue sarcomas.
The results reported were from an analysis of a phase 3 clinical study in which 341 high-grade sarcoma patients were enrolled and randomised into two groups, the control group receiving chemotherapy alone and the experimental group receiving chemotherapy plus hyperthermia.

The study concluded that disease-free survival and local progression-free survival were significantly improved in the experimental group.

The particular focus of the presentation was reducing the risk of early disease progression, as that is a major objective in treating soft-tissue sarcoma patients, a particularly aggressive form of cancer. The clinical study showed a 94.6 percent local progression-free survival (LPFS) rate at three months for the combined hyperthermia/chemotherapy group, as compared to 86.0 percent for the group receiving chemotherapy alone.

At six months the LPFS rate was 91.4 percent for the combined therapy group, as compared to 77.8 percent for the group receiving chemotherapy alone. Disease-free survival was also significantly higher for patients given the combination therapy at both 3 and 6 months (94.0 percent vs. 83.1 percent at three-months and 87.7 percent vs. 73.8 percent at 6-months, comparing the combined therapy to chemotherapy alone). It should be observed that a previous abstract of the study estimated that the median LPFS time approximately doubled for the combined therapy group.

The lead investigator of the study was Rolf Issels, MD, PhD, who is a professor at University Hospital Medical Center Grosshadern, Ludwig Maximilian University, Munich, Germany. Funding for the study was provided by Deutsche Krebshilfe (German Cancer Aid) and the Helmholtz-Gemeinschaft Deutscher Forschungszentren (Helmholtz Association of German Research Centers). All hyperthermia treatments for this study were given using BSD-2000 systems.

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo